Kelly CRISPR & Gene Editing Technology ETF
Kelly CRISPR & Gene Editing Technology ETF
ETF · CA46437W1059 · XDNA (XNAS)
Overview
No Price
n/a

Performance

Day Week Month 3 Months 6 Months 1 Year 5 Years
- - - - 0,00 % 0,00 % -48,03 %

Company Profile for Kelly CRISPR & Gene Editing Technology ETF ETF

The adviser employs a “passive management” investment approach designed to track the total return performance of the index. The index is a rules-based index that consists of the stocks or corresponding depositary receipts of companies engaged in the creation, development, production, operation, provision, distribution, ownership, servicing, licensing, leasing or franchising of at least one of the DNA Modification Technology Business. The fund invests at least 80% of its net assets in DNA Modification Technology Companies. It is non-diversified.

Company Data

Name Kelly CRISPR & Gene Editing Technology ETF
Company Kelly CRISPR & Gene Editing Technology ETF
Symbol XDNA
Primary Exchange XNAS NASDAQ
ISIN CA46437W1059
Asset Class ETF
Sector Financial Services
Industry Asset Management
Currency USD
Employees -
IPO Date 2022-01-13

Ticker Symbols

Name Symbol
NASDAQ XDNA

More Shares

Investors who Kelly CRISPR & Gene Editing Technology ETF hold also have the following shares in their portfolio:
LB.HESS.THR.CARRARA10H/24
LB.HESS.THR.CARRARA10H/24 Bond
TREMONT MORTGAGE TRUST OF BENEFICIAL INTEREST
TREMONT MORTGAGE TRUST OF BENEFICIAL INTEREST Share
The financial platform MoneyPeak tracks and analyzes investments and portfolios. From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Imprint Data Protection Blog Community Feedback Changelog
Im App Store herunterladen Bei Google Play herunterladen
All rights reserved © LCP GmbH 2025